Canaccord Genuity Starts Chembio Diagnostics (CEMI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Accenture (ACN) call put ratio 1 call to 1.2 puts into quarter results
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Chembio Diagnostics (CEMI) Secures CE Mark for Point-of-Care Diagnostic Test Developed in Collaboration with AstraZeneca (AZN)
January 7, 2019 7:22 AM ESTChembio Diagnostics, Inc. (NASDAQ: CEMI) today announced that it has received a CE mark for its diagnostic test developed in collaboration with AstraZeneca, a global biopharmaceutical company.
Chembio and AstraZeneca have collaborated to develop a quantitative diagnostic test to detect an... More
